ACET: Adicet Bio Inc. Price to Sales
Adicet Bio is developing affordable lymphoma therapy through T-cell programming, making the asset promising. The price-to-sales ratio on the chart confirms this trend, with the current level sitting around 10.80. Production relies on California-based centers and CDMO partners, while patent protection and FDA certification complexities create a significant barrier to entry for new market players.
Analytical breakdowns for Adicet Bio (ACET)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Adicet Bio|ACET - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio adicetbio.com|ACET - Company Aggregate Debts|Debts to Book Value Adicet|ACET - Company Long-Term Liabilities|Amount of Current Liabilities Adicet Bio|Intermediate Coverage Ratio adicetbio.com
- company profitability and valuation multiples indicators:
ACET - Net Profit|Expected Profit Adicet Bio|ACET - P/E Multiple|Market Cap to Projected Earnings adicetbio.com|ACET - Price/Earnings to Growth Ratio|Company Value to EBITDA Adicet|ACET - Operating profit EBITDA|Net earnings per share (EPS TTM) Adicet Bio|ACET - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months adicetbio.com|ACET - Earnings growth in current year|Expected net earnings per share growth next year Adicet Bio
- issuer revenue and sales details:
General company analysis:ACET - Adicet Bio Inc.
Adicet Bio occupies the niche of a cell therapy developer whose valuation currently depends on the prospects of clinical trials. Analyzing the fundamental P/S ratio allows an investor to see the relationship between market capitalization and annual revenue. An increase in this ratio amid stagnant sales indicates speculative overheating, whereas a decrease confirms undervaluation. For Adicet Bio, this metric remains formal until the company acquires real pricing power in the market.
Who Adicet Bio competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|PTGX - P/S Multiple|IMVT: P/S Multiple|Market Cap to Revenue Ratio KNSA|GRFS (Grifols) - P/S Multiple|Adaptive Biotech (ADPT) - Price-to-Revenue Coefficient|P/S Multiple CLDX|Market Cap to Revenue Aurinia Corp AUPH|P/S Multiple BCRX (BioCryst)|veratx.com (VERA) - Price to Sales|DNTH: Market Cap to Revenue|Pharvaris NV - Market Cap to Sales Volume|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|Tourmaline - Market Capitalization-to-Revenue Ratio|PGEN (Precigen, Inc.) - P/S Multiple|Price-to-Revenue Ratio PHAR|P/S Multiple NKTR|Price-to-Revenue Coefficient Upstream Bio, Inc.|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Immunome Bio (IMNM) - Price to Sales|Gossamer Bio, Inc. - P/S Multiple|KALV - P/S Multiple|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharma|SVRA (Savara Corp) - P/S Multiple|Price to Sales Rigel Corp RIGL|Market Cap to Revenue ANAB (AnaptysBio, Inc.)|Market Cap to Sales Volume ATXS|Price-to-Revenue Ratio enGene ENGN|RAPT (RAPT Therapeutics Inc.) - Price-to-Sales Ratio|Aerovate - P/S Multiple|Market Capitalization-to-Revenue Ratio ACRS (Aclaris Therapeutics, Inc)|KYTX: P/S Multiple|tizianalifesciences.com (TLSA) - P/S Multiple|Price-to-Revenue Ratio Cabaletta Bio|VTYX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Theratechnologies Inc (THTX)|Market Cap to Revenue Avalo Therapeutics Inc AVTX|P/S Multiple ELDN (Eledon Pharmaceuticals)|P/S Multiple agenusbio.com AGEN|CLYM: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ZURA (Zura Bio Ltd)|ATYR: P/S Multiple|ADAG - Price-to-Revenue Coefficient|Price-to-Revenue Ratio ImageneBio|Market Cap to Revenue Shattuck Therapeutics (STTK)|Price-to-Revenue Ratio Equillium, Inc. (EQ)|Market Cap to Revenue connectbiopharm.com CNTB|Immunic - Market Cap to Revenue|P/S Multiple Atara Biotherapeutics, Inc. ATRA|IFRX - Price-to-Revenue Ratio|XFOR (x4pharma.com) - Market Cap to Revenue Ratio|CELU: P/S Multiple|Price to Sales INmune Bio Inc (INMB)|BRNS (Barinthus Bio) - P/S Multiple|P/S Multiple Kezar Life Sciences Inc|P/S Multiple SABS|akaritx.com - Market Cap to Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|Price-to-Revenue Coefficient Q32 Bio Inc (QTTB)|GeoVax Labs Inc - P/S Multiple|Edesa Biotech Corp (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|Price to Sales Carisma Therapeutics Inc. (CARM)|Market Cap to Revenue XTLB|BOLT (Bolt Bio) - Market Cap to Sales Volume|Market Cap to Revenue HCWB (HCW Biologics Inc.)|APVO (aptevotherapeutics.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple AIM (AIM ImmunoTech Inc.)|Aditxt Inc. - Price-to-Revenue Ratio|GRI Bio - P/S Multiple|Price-to-Revenue Coefficient XORTX Therapeutics Inc XRTX|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Price to Sales Revelation Biosciences Corp (REVB)|INDP (Indaptus Therapeutics) - P/S Multiple|P/S Multiple scinai.com|P/S Multiple CALI|Market Cap to Revenue affimed.com AFMD|P/S Multiple ALLK (Allakos)|HOOKIPA Pharma, Inc. (HOOK) - Price to Sales|IGMS: Market Cap to Revenue|iteostherapeutics.com - Market Cap to Sales Volume|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Price-to-Sales Ratio TCBP (TC BioPharm (Holdings) Plc)|THRD (Third Harmonic Bio, Inc) - P/S Multiple
